Draft:Newron Pharmaceuticals 2

Newron Pharmaceuticals is an Italian pharmacy research company founded in 1999 and based in Bresso, near Milan. Its shares are traded on the Swiss Stock Exchange. Safinamide, a drug against Parkinson's disease, was approved by the EU and Switzerland in 2015, and in 2017, by the U.S. FDA. Drugs in development are ralfinamide against neuropathic pain, and evenamide to treat schizophrenia.

The largest shareholder of Newron is Zambon, which is also headquartered in Bresso, with 4.41% of the voting rights.